Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G.

AIDS Patient Care STDS. 2009 Dec;23(12):993-9. doi: 10.1089/apc.2009.0153.

2.

Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB.

AIDS Patient Care STDS. 2011 Sep;25(9):533-8. doi: 10.1089/apc.2011.0048. Epub 2011 Aug 8.

3.

Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M.

AIDS Patient Care STDS. 2009 Sep;23(9):715-25. doi: 10.1089/apc.2009.0049.

4.
5.

Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.

Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group.

HIV Med. 2013 Aug;14(7):430-6. doi: 10.1111/hiv.12023. Epub 2013 Mar 5.

6.

Hepatitis C treatment experiences and decision making among patients living with HIV infection.

Bova C, Ogawa LF, Sullivan-Bolyai S.

J Assoc Nurses AIDS Care. 2010 Jan-Feb;21(1):63-74. doi: 10.1016/j.jana.2009.07.009. Epub 2009 Oct 22.

7.

Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.

Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group.

Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12.

PMID:
21819472
8.
9.

Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Wagner G, Osilla KC, Garnett J, Ghosh-Dastidar B, Bhatti L, Witt M, Goetz MB.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):245-51. doi: 10.1177/1545109712444163. Epub 2012 May 7.

10.

Challenges facing providers caring for HIV/HCV-coinfected patients.

Lekas HM, Siegel K, Leider J.

Qual Health Res. 2012 Jan;22(1):54-66. doi: 10.1177/1049732311418248. Epub 2011 Aug 8.

11.

Treatment of hepatitis C virus in the coinfected patient.

Brennan C.

J Assoc Nurses AIDS Care. 2003 Sep-Oct;14(5 Suppl):52S-79S. Review.

PMID:
14571561
12.

Hepatitis C Virus in the HIV-infected patient.

Andersson K, Chung RT.

Clin Liver Dis. 2006 May;10(2):303-20, viii. Review.

PMID:
16971263
14.

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.

Braun DL, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Metzner KJ, Böni J, Weber R, Fehr J.

HIV Med. 2014 Nov;15(10):625-30. doi: 10.1111/hiv.12166. Epub 2014 Jun 4.

15.

HCV treatment decision-making substance use experiences and hepatitis C treatment decision-making among HIV/HCV Coinfected Adults.

Ogawa LM, Bova C.

Subst Use Misuse. 2009;44(7):915-33. doi: 10.1080/10826080802486897.

PMID:
19440928
16.

Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons.

Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR.

AIDS. 2005 Oct;19 Suppl 3:S208-14.

PMID:
16251820
17.
18.

Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients.

Medrano J, Resino S, Vispo E, Madejón A, Labarga P, Tuma P, Martín-Carbonero L, Barreiro P, Rodriguez-Novoa S, Jiménez-Nacher I, Soriano V.

J Viral Hepat. 2011 May;18(5):325-30. doi: 10.1111/j.1365-2893.2010.01309.x.

PMID:
20456635
19.

Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.

Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA.

J Virol. 2011 Jun;85(12):5961-9. doi: 10.1128/JVI.00308-11. Epub 2011 Apr 6.

20.

Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.

Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, Ojanguren I, Barluenga E, Videla S, Planas R, Clotet B, Tural C.

HIV Med. 2014 Apr;15(4):203-12. doi: 10.1111/hiv.12105. Epub 2013 Nov 19.

Supplemental Content

Support Center